Constitutional Issues,
Consumer Issues,
Economic Development,
Federal-Provincial Relations,
Government Procurement,
Health,
Research and Development,
Science and Technology,
Small Business,
Taxation and Finance
|
To amend The Cannabis Act (S.C. 2018, c. 16), to regulate Cannabidiol (CBD) as a Natural Health Product (NHP), and to include Cannabidiol (CBD) under Schedule 1 substances such as herbs, vitamins, essential fatty acids that are considered appropriate as ingredients in NHPs; whereas Cannabidiol (CBD), is one of a group of chemical substances called cannabinoids and are found in the flowers and leaves of the Cannabis plant. Unlike the more widely known cannabinoid, delta-9 tetrahydrocannabinol or THC, CBD does not produce the classic “high” or intoxication. CBD has been touted for a wide variety of health issues, but the strongest scientific evidence is for its effectiveness in treating some of the cruelest childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), which typically do not respond to antiseizure medications. In numerous studies, CBD was able to reduce the number of seizures, and, in some cases, it was able to stop them altogether.
|